Chinese Heparin Subject Of U.S. Congress Hearing
This article was originally published in PharmAsia News
The CEO of Baxter International is set to testify before a congressional hearing April 29 on the firm's contaminated heparin from China. Baxter's version of the blood thinner was linked to at least 81 deaths, the problem traced to a single source in China and said to have been deliberate. The title of the House Oversight and Investigations Subcommittee hearing is, "The Heparin Disaster: Chinese Counterfeits and American Failures." Baxter CEO Robert Parkinson and the CEO of the Chinese supplier, Scientific Protein Labs, were on the witness list. (Click here for more
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.